Filing Flows

Filing Flows › Health Care › Biomerica (BMRA)

Biomerica (BMRA) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Oct 15, 2026 · Biomerica (BMRA) Q1 FY27 earnings results →

Q1 FY27 Revenue down 8% year over year to $1.3M · 97¢ of every $1 of revenue lost · operating margin -97.0%

Biomerica made $1.3M in Q1 FY27 (-8% Y/Y): Clinical Lab $775K, Over-the-counter $291K, Contract Manufacturing $197K. Operating margin -97.0%, net loss $1.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 15, 2026.

Revenue$1.3M
Year over year-8%
Operating margin-97.0%
Net earnings−$1.2M
Operating cash flow−$802K

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $1.3M in Q1 FY27, down 8% year over year and up 45% from the previous quarter. Clinical Lab was the largest line at 61% of revenue. Clinical Lab lost $249K year over year (down 24%), 217% of the total change.

Gross margin was 8.1%, down 22.6 points from Q1 FY26. Operating costs exceeded revenue by $1.2M, an operating margin of -97.0%. Operating expenses fell 14% while revenue fell 8%. The quarter ended with a net loss of $1.2M, wider than the previous quarter's $1.1M loss.

Operating cash flow was −$802K. Non-cash charges added back $15K of depreciation and amortization and $134K of share-based compensation. Working capital and other items added $281K.

Quarterly history

Biomerica revenue by quarterBiomerica revenue by quarter$1.1MQ3 FY25$749KQ4 FY25$1.4MQ1 FY26$1.2MQ2 FY26$987KQ3 FY26$875KQ4 FY26$1.3MQ1 FY27
Biomerica net earnings by quarterBiomerica net earnings by quarter−$1.2MQ3 FY25−$1.5MQ4 FY25$2KQ1 FY26−$1.3MQ2 FY26−$1.3MQ3 FY26−$1.1MQ4 FY26−$1.2MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QOct 15, 2026$1.3M-8%-97.0%−$1.2M−$802K
Q4 FY2610-KAug 31, 2026$875K+17%-175.2%−$1.1M−$912K
Q3 FY2610-QApr 13, 2026$987K-12%-131.5%−$1.3M−$1.2M
Q2 FY2610-QJan 14, 2026$1.2M-26%-113.5%−$1.3M−$991K
Q1 FY2610-QOct 14, 2025$1.4M-24%-81.0%$2K−$268K
Q4 FY2510-KAug 29, 2025$749K-33%-208.8%−$1.5M−$662K
Q3 FY2510-QApr 14, 2025$1.1M+10%-108.1%−$1.2M−$1.0M

Charts

Biomerica: revenue growth, year over year and quarter over quarterBiomerica: revenue growth, year over year and quarter over quarterY/YQ/Q+10%Q3 FY25-33%-33%Q4 FY25-24%+84%Q1 FY26-26%-12%Q2 FY26-12%-18%Q3 FY26+17%-11%Q4 FY26-8%+45%Q1 FY27
Latest (Q1 FY27): Y/Y -8%, Q/Q +45%.
Biomerica: where the cash came from (+) and went (−), TTM to Q1 FY27Biomerica: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow−$4.0MShares issued$3.2MOther financing$479KCash drawn (+) / kept (−)$320KExchange rates−$9KNot reconciled−$1K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Biomerica: profit against cash, quarter by quarterBiomerica: profit against cash, quarter by quarterNet incomeOperating cash flow−$950K−$791KQ2 FY25−$1.2M−$1.0MQ3 FY25−$1.5M−$662KQ4 FY25$2K−$268KQ1 FY26−$1.3M−$991KQ2 FY26−$1.3M−$1.2MQ3 FY26−$1.1M−$912KQ4 FY26−$1.2M−$802KQ1 FY27
Latest (Q1 FY27): Net income −$1.2M, Operating cash flow −$802K.
Biomerica: diluted shares by fiscal yearBiomerica: diluted shares by fiscal year12MFY2113MFY2214MFY232MFY242MFY253MFY26
-75.6% since FY21: buybacks shrank the count.
Biomerica in its industry: growth against margin (15 companies, SIC 2835)Biomerica in its industry: growth against margin (15 companies, SIC 2835)revenue growth, year over year →↑ operating marginmedian -2%median -90%IDXXQDELLNTHNEOGMYGNTKNOICCCNTLAAWHLIonetix CorpVNRXIMDXCLDXCDIOBMRA (-8%, -97%)
In Vitro & In Vivo Diagnostic Substances; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Biomerica

We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions. These tests detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances that may exist in the human body at extremely low concentrations. Our products are designed to enhance patient outcomes and well-being while reducing total healthcare costs.

In its own words, from its 10-K, filed Aug 31, 2026.

Biomerica against its In Vitro & In Vivo Diagnostic Substances peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -8% against the peers' median +2%. Operating margin: -97.0% against the peers' median -1.2%.

CompanyQuarterRevenueY/YOp. margin
BMRA BiomericaQ1 FY27$1.3M-8%-97.0%
IDXX Idexx LaboratoriesQ3 2026$1.2B+10%33.1%
QDEL QuidelOrthoQ3 2026$619M-12%-1.2%
LNTH Lantheus HoldingsQ3 2026$390M+2%8.3%
NEOG NeogenQ1 FY27$223M+6%-0.8%
MYGN Myriad GeneticsQ3 2026$203M-2%-19.7%
TKNO Alpha TeknovaQ3 2026$12.7M+22%-25.2%
ICCC ImmucellQ2 2026$7.2M+12%26.9%
NTLA Intellia TherapeuticsQ3 2026$7.2M-48%n/m

Source: Biomerica 10-Q on SEC EDGAR · CIK 73290 · In Vitro & In Vivo Diagnostic Substances

13F: who owns BMRA and who is buying

Largest holders of BMRA (13F)Largest holders of BMRA (13F)Vanguard Group$53KGeode Capital Management, LLC$43KBlackRock$33KVanguard Capital Management LLC$26KJane Street Group, LLC$22KLPL Financial LLC$19KUBS Group AG$12KVanguard Fiduciary Trust$12KBerthel, Fisher & Company Financi…$8KNewEdge Advisors, LLC$6K
Funds' net buying of BMRA by quarter (13F)Funds' net buying of BMRA by quarter (13F)$6K2025-03$192K2025-06$66K2025-09−$5K2025-12$97K2026-03$28K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on BMRA

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare BMRA with

中文版：Biomerica（BMRA）财报

Español · Français